Supplemental_Material – Supplemental material for “Cannot see? Use your strengths!” A randomized controlled trial of strengths intervention for improving self-esteem among visually impaired individuals

Supplemental material, Supplemental_Material for “Cannot see? Use your strengths!” A randomized controlled trial of strengths intervention for improving self-esteem among visually impaired individuals by Shinichiro Matsuguma, Motoko Kawashima, Fumiya Sano and Kazuo Tsubota in Clinical Rehabilitation</p

ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline

One of the difficulties in developing a novel drug for patients with amyotrophic lateral sclerosis (ALS) is the significant variation in the clinical course. To control this variation, a 12-week run-in period is used in some clinical trials. Based on the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) change during the run-in period, only moderate progressors are selected in some clinical trials. Some reports showed that the ALSFRS-R progression rate was associated with survival. However, it is unclear whether the ALSFRS-R change in the run-in period is a useful prognostic factor of the ALSFRS-R change from baseline. In addition, we explore the inclusion criteria that could control the variability in ALS-function progression without setting a run-in period. We utilized the Japanese and US ALS registry databases (JaCALS and PRO-ACT). Patients were classified into three populations (rapid, moderate, and slow progressors) based on the ALSFRS-R change prior to baseline. We also classified patients into three prognostic populations based on the ALSFRS-R change from baseline. We confirmed whether each of the three populations were matched with their respective three prognostic populations. Our data showed that the three groups classified by the ALSFRS-R change during the 12 weeks prior to baseline or by the rate of progression from onset to baseline did not accord with the three prognostic groups. Our results showed that the ALSFRS-R change in the run-in period or from onset to baseline is not useful for stratifying subsequent progression of functional decline in clinical trials.</p